112 related articles for article (PubMed ID: 16910410)
1. [Lowering blood pressure substantially--and the diabetes risk as well?].
MMW Fortschr Med; 2006 Jul; 148(29-30):48-9. PubMed ID: 16910410
[No Abstract] [Full Text] [Related]
2. [Despite drug treatment, ever second hypertensive patient with morning blood pressure too high].
MMW Fortschr Med; 2004 Aug; 146(33-34):52. PubMed ID: 15526635
[No Abstract] [Full Text] [Related]
3. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
[No Abstract] [Full Text] [Related]
4. [AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
MMW Fortschr Med; 2003 Apr; 145(15):62. PubMed ID: 15104271
[No Abstract] [Full Text] [Related]
5. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ].
Bramlage P; Schönrock E; Odoj P; Wolf WP; Funken C
MMW Fortschr Med; 2008 Feb; 150(6):40. PubMed ID: 18323344
[No Abstract] [Full Text] [Related]
6. Effects of angiotensin II receptor blockers on the relationships between ambulatory blood pressure and anti-hypertensive effects, autonomic function, and health-related quality of life.
Okano Y; Tamura K; Masuda S; Ozawa M; Tochikubo O; Umemura S
Clin Exp Hypertens; 2009 Nov; 31(8):680-9. PubMed ID: 20001460
[TBL] [Abstract][Full Text] [Related]
7. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
Serebruany VL; Atar D; Hanley DF
Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
[No Abstract] [Full Text] [Related]
9. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
10. [Lowering blood pressure with sartans. Are there differences?].
MMW Fortschr Med; 2002 Nov; 144(47):63. PubMed ID: 12532530
[No Abstract] [Full Text] [Related]
11. The X-cellent Study.
Safar ME
Am J Hypertens; 2006 Jan; 19(1):8-9. PubMed ID: 16461182
[No Abstract] [Full Text] [Related]
12. Effects of angiotensin II receptor blockers on relationships between 24-hour blood pressure, autonomic function, and health-related QOL.
Okano Y; Tamura K; Kuji T; Masuda S; Tochikubo O; Umemura S
Clin Exp Hypertens; 2009 May; 31(3):250-8. PubMed ID: 19387901
[TBL] [Abstract][Full Text] [Related]
13. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.
Nakayama S; Watada H; Mita T; Ikeda F; Shimizu T; Uchino H; Fujitani Y; Hirose T; Kawamori R
Hypertens Res; 2008 Jan; 31(1):7-13. PubMed ID: 18360012
[TBL] [Abstract][Full Text] [Related]
14. [Risk oriented therapy of hypertension. Lowering blood pressure and risk].
MMW Fortschr Med; 2007 Nov; 149(46):53. PubMed ID: 18069196
[No Abstract] [Full Text] [Related]
15. Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.
Volpe M
Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):1061-72. PubMed ID: 23030295
[TBL] [Abstract][Full Text] [Related]
16. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients.
Fogari R; Mugellini A; Zoppi A; Lazzari P; Destro M; Rinaldi A; Preti P
J Hum Hypertens; 2006 Mar; 20(3):177-85. PubMed ID: 16306998
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial rigging: again!
Prescrire Int; 2014 Apr; 23(148):110. PubMed ID: 24860906
[No Abstract] [Full Text] [Related]
18. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
Shigenaga A; Tamura K; Dejima T; Ozawa M; Wakui H; Masuda S; Azuma K; Tsurumi-Ikeya Y; Mitsuhashi H; Okano Y; Kokuho T; Sugano T; Ishigami T; Toya Y; Uchino K; Tokita Y; Umemura S
Nephron Clin Pract; 2009; 112(1):c31-40. PubMed ID: 19342867
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan provides superior BP reduction from morning to morning compared to other leading ARBs.
Cardiovasc J S Afr; 2006; 17(4):210. PubMed ID: 17001428
[No Abstract] [Full Text] [Related]
20. ACE inhibitors in cardiovascular disease--unbeatable?
McMurray JJ
N Engl J Med; 2008 Apr; 358(15):1615-6. PubMed ID: 18378521
[No Abstract] [Full Text] [Related]
[Next] [New Search]
